Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients
Bicycle Therapeutics plc (NASDAQ:BCYC) announced that it presented data showing the enhanced anti-tumor activity of ...
Medindia9d
Cell-Free DNA in Urine: A New Biomarker for UTUC Detection
Discover how voided urine cfDNA emerges as a promising biomarker for upper tract urothelial carcinoma, offering a less ...
dvm3602d
Understanding transitional cell carcinoma in canine patients
Craig A Clifford, DVM, MS, DACVIM (Oncology) talks about the most common bladder tumor in dogs, misdiagnosis, and the Cadet ...
FDA Grants Breakthrough Therapy Status To Gilead's Trodelvy For Treatment Of Small Cell Lung Cancer
(RTTNews) - Gilead Sciences, Inc. (GILD) Tuesday said that the U.S. Food and Drug Administration or FDA has granted Breakthrough Therapy Designation to Trodelvy for the treatment of adults with ...
GDF-15 inhibitors show promise against hard-to-treat tumors in clinical trial
A multi-institutional clinical trial led by the University of Navarra, Spain, found that blocking growth differentiation ...
Oncology Nurse Advisor14h
Adjuvant Nivolumab Improves Outcomes in High-Risk MIUC
Updated results from the CheckMate 274 trial support the use of adjuvant nivolumab as standard care for high-risk muscle-invasive urothelial carcinoma, according to researchers.
Dogs look out for one another: Study shows that dogs can smell cancer in other dogs
The results of a study into whether cancer detection dogs can smell bladder cancer in other dogs' urine suggests that this ...
earth9d
Trained dogs can detect cancer in other dogs, as well as in people
Dogs trained to detect bladder cancer showed 90% sensitivity and 95% specificity, offering a non-invasive diagnostic method.
techexplorist11d
Dogs can smell bladder cancer in other dogs
Urothelial carcinoma (UC), also known as transitional cell carcinoma (TCC), is the most common form of bladder cancer in dogs ...
Business Wire13d
Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specia ...
The Pharma Letter1d
FDA Breakthrough status for Trodelvy in ES-SCLC
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Trodelvy (sacituzumab ...
Bicycle Therapeutics plc Discloses Development Strategy Leveraging NECTIN4 Gene Amplification
Bicycle Therapeutics plc, a company specializing in developing therapeutic solutions based on its proprietary bicyclic peptide technology, revealed significant data updates across its zelenectide ...